Qian Yuan Baixing, Inc. (QYBX) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Qian Yuan Baixing, Inc. (QYBX) trades at $0.0093 with AI Score 39/100 (Grade D). Qian Yuan Baixing, Inc. operates within the financial services sector, focusing on the medical equipment diagnostic and biotech business. Formerly known as MDCorp. Sector: Financial services.
Price as of Aug 21, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for QYBX: QYBX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates QYBX against Financial Services peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
QYBX: this read rests on a single discipline (MoonshotScore) — the other council disciplines have no scored data yet.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Qian Yuan Baixing, Inc. (QYBX) Financial Services Profile
Qian Yuan Baixing, Inc., formerly MDCorp., operates in the medical equipment diagnostic and biotech sectors. Based in Seattle, the company navigates the shell company landscape with a focus on niche markets, facing competition from larger, more established financial service providers and biotech firms.
What Is the Investment Thesis for QYBX?
Qian Yuan Baixing, Inc. presents a speculative investment opportunity within the financial services sector, specifically targeting the medical equipment diagnostic and biotech business. With a market capitalization of $0.00B and a P/E ratio of 3.66, the company's valuation metrics require careful scrutiny. A profit margin of 5.6% and a gross margin of 17.0% indicate potential areas for improvement in operational efficiency. The company's beta of -0.44 suggests a negative correlation with the broader market, which could offer some downside protection during market downturns. However, the absence of a dividend yield may deter income-seeking investors. Growth catalysts for Qian Yuan Baixing include successful development and commercialization of new diagnostic technologies or strategic partnerships within the biotech industry. Potential risks include regulatory challenges, competition from larger players, and the inherent uncertainties associated with shell companies. Investors should conduct thorough due diligence to assess the company's financial health, management team, and long-term growth prospects.
Based on FMP financials and quantitative analysis
QYBX Key Highlights
Market capitalization of $0.00B indicates a micro-cap company with significant growth potential but also higher risk.
- P/E ratio of 3.66 suggests the company may be undervalued compared to its earnings, but requires further investigation into earnings sustainability.
- Profit margin of 5.6% highlights the need for improved operational efficiency to enhance profitability.
- Gross margin of 17.0% indicates the company's ability to generate revenue from its products and services, but also suggests room for improvement in cost management.
- Beta of -0.44 suggests the stock has a negative correlation with the market, potentially offering some downside protection.
Who Are QYBX's Competitors?
QYBX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| AGGI Allied Energy, Inc. | $2.25 | +32.24% | $45.4B | 61 |
| NIHL New Infinity Holdings, Ltd. | $0.10 | +0.00% | $10.8M | 62 |
| LRGR Luminar Media Group, Inc. | $0.50 | +47.06% | $22.4M | 68 |
| CLAYU Chavant Capital Acquisition Corp. | $10.97 | +18.34% | $27.5M | 62 |
| CLAY Chavant Capital Acquisition Corp. | $10.66 | +6.39% | $29.6M | 62 |
| INACU Indigo Acquisition Corp. | $12.08 | +16.94% | $34.9M | 60 |
| HHGC HHG Capital Corporation | $11.12 | +0.09% | $56.2M | 63 |
| MAAQ Mana Capital Acquisition Corp. | $5.99 | -24.18% | $57.0M | 61 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are QYBX's Key Strengths?
Focus on medical equipment diagnostics and biotech.
- Potential for innovation in diagnostic technologies.
- Strategic location in Seattle, a biotech hub.
- Low beta suggesting potential downside protection.
What Are QYBX's Weaknesses?
Small market capitalization and limited resources.
- Dependence on successful development and commercialization of new products.
- Potential regulatory challenges and compliance costs.
- Limited operating history as Qian Yuan Baixing, Inc.
What Could Drive QYBX Stock Higher?
Potential development and commercialization of new diagnostic technologies.
- Strategic partnerships within the biotech industry.
- Geographic expansion into emerging markets.
- Acquisition of complementary businesses.
- Focus on personalized medicine and precision diagnostics.
What Are the Key Risks for QYBX?
Financial-distress signal — its Altman Z-Score of -2.19 sits in the distress zone (elevated bankruptcy risk).
- Competition from larger, more established companies.
- Rapid technological advancements that could render existing products obsolete.
- Changes in healthcare regulations and reimbursement policies.
- Economic downturns that could reduce healthcare spending.
- Risks associated with being a shell company and operating on the OTC Other market.
What Are the Growth Opportunities for QYBX?
- Expansion into New Diagnostic Technologies: Qian Yuan Baixing, Inc. can pursue growth by investing in the development and commercialization of innovative medical equipment diagnostic technologies. The global medical device market is projected to reach $600 billion by 2028, offering a substantial opportunity for companies with cutting-edge diagnostic solutions. Successful development and adoption of new technologies could drive revenue growth and enhance the company's market position. Timeline: 2-3 years for product development and regulatory approvals.
- Strategic Partnerships within the Biotech Industry: Collaborating with established biotech companies can provide Qian Yuan Baixing, Inc. with access to new markets, technologies, and expertise. Strategic alliances can accelerate product development, expand distribution channels, and enhance the company's credibility. The biotech industry is experiencing rapid growth, driven by advancements in genomics, personalized medicine, and drug discovery. Timeline: Ongoing, with potential partnerships emerging within the next 1-2 years.
- Geographic Expansion into Emerging Markets: Qian Yuan Baixing, Inc. can explore opportunities to expand its operations into emerging markets with growing healthcare needs. Countries like China, India, and Brazil offer significant potential for medical equipment diagnostic and biotech companies. Entering these markets can diversify revenue streams and reduce reliance on domestic markets. Timeline: 3-5 years for market entry and establishment of operations.
- Acquisition of Complementary Businesses: Qian Yuan Baixing, Inc. can pursue growth through strategic acquisitions of companies with complementary technologies or market access. Acquiring businesses in related fields can expand the company's product portfolio, enhance its competitive position, and create synergies. The M&A market in the healthcare sector remains active, providing opportunities for strategic acquisitions. Timeline: Opportunistic, with potential acquisitions occurring within the next 2-3 years.
- Focus on Personalized Medicine and Precision Diagnostics: The growing trend towards personalized medicine and precision diagnostics presents a significant growth opportunity for Qian Yuan Baixing, Inc. By developing diagnostic tools that can tailor treatments to individual patients, the company can capture a share of this rapidly expanding market. The personalized medicine market is projected to reach $2.4 trillion by 2030, driven by advancements in genomics and data analytics. Timeline: Ongoing, with continuous development of personalized diagnostic solutions.
What Are QYBX's Competitive Advantages?
- Proprietary diagnostic technologies.
- Strategic partnerships within the biotech industry.
- Expertise in navigating the regulatory landscape for medical devices.
- Potential first-mover advantage in niche markets.
What Does QYBX Do?
Qian Yuan Baixing, Inc., established in 2005 and based in Seattle, Washington, operates within the financial services sector, concentrating on the medical equipment diagnostic and biotech business. Originally founded as MDCorp., the company underwent a name change in May 2018 to Qian Yuan Baixing, Inc., signaling a strategic shift or rebranding effort. The company's focus on medical equipment diagnostics and biotech positions it within a specialized segment of the broader healthcare industry. As a shell company, Qian Yuan Baixing's operations and financial structure may differ significantly from traditional operating companies. The company's relatively small size, indicated by its 15 employees, suggests a lean operational model. Its location in Seattle, a hub for biotech and technology companies, provides access to talent and potential partnerships. However, it also faces competition from established players in both the financial services and biotech sectors. The company's evolution from MDCorp. to Qian Yuan Baixing reflects its ongoing efforts to adapt and capitalize on opportunities within its chosen markets. The company's success hinges on its ability to effectively navigate the complexities of the shell company landscape while delivering value in the medical equipment diagnostic and biotech space.
What Products and Services Does QYBX Offer?
- Focuses on the medical equipment diagnostic business.
- Operates within the biotech industry.
- Develops and commercializes diagnostic technologies.
- Seeks strategic partnerships within the healthcare sector.
- Potentially explores opportunities in personalized medicine.
- Navigates the complexities of being a shell company.
How Does QYBX Make Money?
- Generates revenue through the sale of medical equipment diagnostic products.
- Potentially licenses its technologies to other companies.
- May receive funding through investments and partnerships.
- Focuses on research and development to create new diagnostic solutions.
What Industry Does QYBX Operate In?
Qian Yuan Baixing, Inc. operates within the shell company segment of the financial services sector, a niche market characterized by unique regulatory and operational considerations. The industry is influenced by broader trends in healthcare, biotech, and financial regulations. Competition comes from both established financial institutions and emerging biotech companies. The company's success depends on its ability to navigate the complexities of the shell company landscape while capitalizing on opportunities in the medical equipment diagnostic and biotech sectors. Given the speculative nature of shell companies, investors should exercise caution and conduct thorough due diligence.
Who Are QYBX's Key Customers?
- Hospitals and clinics that use medical equipment for diagnostics.
- Research institutions conducting biotech research.
- Healthcare providers seeking personalized medicine solutions.
- Potential partners in the biotech and pharmaceutical industries.
Company Profile
Qian Yuan Baixing, Inc. operates in the Consumer Electronics industry within the Technology sector. It is headquartered in Seattle, US. The company is led by CEO Zhi Cao. QYBX has traded publicly since 2008.
How Qian Yuan Baixing, Inc. Is Valued
Relative to its peer group, QYBX's quantitative score of 39/100 is below the peer average of 63/100.
Key Financial Metrics
Return on equity for Qian Yuan Baixing, Inc. stands at 9.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 4.5%, showing how much profit it generates from its asset base. QYBX trades at a trailing price-to-earnings ratio of 4.55, below the Financial Services sector average of ~18x. Its free cash flow yield is 25.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.96 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 22.0%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Qian Yuan Baixing, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -2.19 places it in the distress zone, a signal of elevated financial risk.
QYBX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- QYBX insiders seem to be positioning themselves for potential growth, which often signals confidence in the company's future prospects.
- The community is buzzing about potential new partnerships that could significantly expand QYBX's market reach.
- There's a growing narrative that QYBX is undervalued, with many seeing it as a hidden gem in its sector.
- Recent developments suggest QYBX might be adapting well to changing market conditions, sparking optimism among investors.
Bear Case
- Some community members are concerned about increasing competition affecting QYBX's market share.
- There's a perception that QYBX's growth strategy might be too aggressive, potentially leading to financial strain.
- Negative sentiment is building around recent regulatory changes that could disproportionately impact QYBX's operations.
- Despite positive developments, skepticism remains regarding QYBX's ability to maintain its current momentum given broader economic uncertainties.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
QYBX Latest News
No recent news available for QYBX.
QYBX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for QYBX.
Price Targets
Wall Street price target analysis for QYBX.
QYBX MoonshotScore
What does this score mean?
The MoonshotScore rates QYBX 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Classification
Industry Shell CompaniesLeadership: Tim Alford
CEO
Tim Alford serves as the CEO of Qian Yuan Baixing, Inc., leading a team of 15 employees. Information regarding his detailed career history, educational background, and previous roles is not available. His leadership is crucial for guiding the company's strategic direction and operational execution within the competitive financial services and biotech sectors. Further information on his credentials and experience would provide a more comprehensive understanding of his capabilities.
Track Record: Due to limited information, Tim Alford's specific achievements, strategic decisions, and company milestones under his leadership are unknown. Assessing his track record would require further data on the company's performance and key initiatives during his tenure. His ability to drive growth, manage risk, and create shareholder value remains to be evaluated.
QYBX OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Qian Yuan Baixing, Inc. may not meet the minimum financial standards or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may be subject to greater price volatility. Investing in OTC Other stocks carries significant risks due to the lack of regulatory oversight and potential for fraud or manipulation. Investors should exercise extreme caution and conduct thorough due diligence before investing in companies on this tier.
- OTC Tier: OTC Other
- Limited regulatory oversight and disclosure requirements.
- Potential for fraud or manipulation due to lack of transparency.
- High price volatility and illiquidity.
- Uncertainty regarding the company's financial health and long-term viability.
- Risk of delisting or trading suspension.
- Verify the company's registration and legal status.
- Obtain and review all available financial reports and disclosures.
- Assess the company's management team and their track record.
- Evaluate the company's business model and competitive landscape.
- Determine the company's compliance with applicable regulations.
- Understand the risks associated with investing in OTC Other stocks.
- Consult with a qualified financial advisor.
- Company has been in operation since 2005.
- Focus on medical equipment diagnostics and biotech.
- Presence in Seattle, a hub for biotech companies.
- Name change in 2018 suggests a strategic shift.
Common Questions About QYBX (Financial Services)
What does the AI Score mean for QYBX?
QYBX holds an AI Score of 39/100 (Grade: D). This is an educational research signal, not a buy or sell recommendation. Qian Yuan Baixing, Inc. operates within the financial services sector, focusing on the medical equipment diagnostic and biotech business. Formerly known as MDCorp., the company is based in Seattle …
What does Qian Yuan Baixing, Inc. do?
Qian Yuan Baixing, Inc. operates in the financial services sector, with a focus on the medical equipment diagnostic and biotech business. The company aims to develop and commercialize diagnostic technologies, potentially partnering with other biotech firms to expand its market reach. As a shell company, it navigates a unique regulatory landscape, seeking opportunities for growth within its chosen niche.
What do analysts say about QYBX stock?
As of 2026-03-17, there is no readily available analyst coverage for Qian Yuan Baixing, Inc. This lack of coverage is typical for OTC-listed companies, especially those with a small market capitalization. Investors should rely on their own due diligence and independent research to assess the company's prospects.
What are the main risks for QYBX?
Qian Yuan Baixing, Inc. faces several risks, including competition from larger, more established companies in the medical equipment diagnostic and biotech sectors. Rapid technological advancements could render the company's products obsolete. Changes in healthcare regulations and reimbursement policies could negatively impact its revenue.
How is Qian Yuan Baixing, Inc. adapting to fintech disruption?
Given Qian Yuan Baixing, Inc.'s focus on medical equipment diagnostics and biotech, its exposure to direct fintech disruption may be limited compared to traditional financial institutions. However, the company can leverage fintech solutions to improve its operational efficiency, enhance data analytics capabilities, and streamline its financial processes. Embracing digital technologies can help Qian Yuan Baixing, Inc.
What regulatory challenges does Qian Yuan Baixing, Inc. face?
As a company operating in the financial services sector and focusing on medical equipment diagnostics and biotech, Qian Yuan Baixing, Inc. faces a complex regulatory environment. Compliance with securities laws, healthcare regulations, and biotech industry standards is crucial. The company must navigate potential challenges related to product approvals, data privacy, and intellectual property protection.
What are the key factors to evaluate for QYBX?
Qian Yuan Baixing, Inc. (QYBX) holds an AI score of 39/100 (low). presents a speculative investment opportunity within the financial services sector, specifically targeting the medical equipment diagnostic and biotech business. Not financial advice.
How frequently does QYBX data refresh on this page?
QYBX's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven QYBX's recent stock price performance?
Qian Yuan Baixing, Inc. (QYBX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on medical equipment diagnostics and biotech. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on Qian Yuan Baixing, Inc.
- OTC Other stocks are inherently riskier investments.
- Lack of analyst coverage requires independent due diligence.